Tezepelumab Cuts Oral Corticosteroid Use in Severe Asthma

(MedPage Today) — Most patients with severe asthma substantially reduced or even discontinued oral corticosteroid use with addition of tezepelumab (Tezspire) in the single-arm WAYFINDER trial.
At both 28 and 52 weeks, 88.9% of patients dropped…